Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Oxytetracycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.70 |
| ▸ | MEN1 | O00255 | 9/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.70 |
| ▸ | USP2 | O75604 | 7/20 | 0.70 |
| ▸ | HPGD | P15428 | 6/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | RECQL | P46063 | 5/20 | 0.70 |
| ▸ | THRB | P10828 | 4/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxytetracycline SCHEMBL2899 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL13782519 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL13782617 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL18048891 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL2614977 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL5507247 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL1292896 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL21133474 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL21133472 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL13782478 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865686-B2 | Tetracycline compounds as tyrosyl-DNA phosphodiesterase I inhibitors | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865686-B2 | Tetracycline compounds as tyrosyl-DNA phosphodiesterase I inhibitors | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2014-10-21 | — | — | US | disclosed |
| US-20090176747-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | NATIONAL INSTITUTES OF HEALTH (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176747-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | NATIONAL INSTITUTES OF HEALTH (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176747-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TDP1, TDP2, TARDBP | TDP1 1/4885MEN1 3718/4885KMT2A 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.